Inmune Bio (INMB) Stock Statistics & Valuation Metrics

Inmune Bio has a market cap or net worth of $57.42M. The enterprise value is $20.90M.

Inmune Bio has 26,585,258 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inmune Bio’s return on equity (ROE) is -1.31 and return on invested capital (ROIC) is -131.26%.

The current PE Ratio of Inmune Bio is ―. Inmune Bio’s PEG ratio is ―.

In the last 12 months, Inmune Bio had revenue of 14.00K and earned -42.08M in profits. Earnings per share was -2.11.

In the last 12 months, operating cash flow was -32.20M and capital expenditures -706.00K, giving a free cash flow of -32.90M billion.

Inmune Bio pays an annual dividend of ―, resulting in a dividend yield of ―

Inmune Bio upcoming earnings date is Oct 29, 2025, TBA (Confirmed).

Inmune Bio as a current ratio of 3.14, with Debt / Equity ratio of 1.56%

In the past 12 months, Inmune Bio has paid 0.00 in taxes.

Inmune Bio EV to EBITDA ratio is -1.73, with an EV/FCF ratio of -2.18.

Inmune Bio has $33.37M in cash and marketable securities with $451.00K in debt, giving a net cash position of -$32.92M billion.

Gross margin is 100.00%, with operating margin of -304535.71%, and net profit margin of -300585.71%.

The average price target for Inmune Bio is $7.72, which is 11.43% higher than the current price. The consensus rating is Hold